In order to determine whether EGFRvIII affects the proneural–mesenchymal transition of GBM cells through the NF-κB pathway, Western blot was used to detect the expression of proneural–mesenchymal-transition-related markers (PN marker SOX2 and MES marker CD44). The gene discussed is CD44; the disease is glioblastoma.